Navigation Links
Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference
Date:11/30/2011

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011.  The conference will be held at the Westin Copley Place in Boston, MA.  Dr. Spana will be presenting an overview on Palatin's Phase 2b trial for bremelanotide in premenopausal women with female sexual dysfunction, and the Phase 1 trial for AZD2820, under development for the treatment of obesity, in collaboration with AstraZeneca.  Bremelanotide, the Company's lead drug candidate, was named one of the "2011 Top Projects to Watch" by Windhover.

ABOUT THE CONFERENCE

Windhover's Therapeutic Area Partnerships conference is a uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking. For more information on the conference and presenting companies please go to http://www.tapartnerships.com.  

ABOUT PALATIN TECHNOLOGIES, INC.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.


 

 


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at 10th Annual BIO Investor Forum
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
5. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
6. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
8. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
9. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
10. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
11. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2019)... ... February 12, 2019 , ... ... has finalized a deal to extend their use of Medrio, the leading provider ... 2023. The CRO has been a regular Medrio customer for over nine years, ...
(Date:2/2/2019)... ... January 31, 2019 , ... Dust off your Doc ... it hosts the Nuriv 2019 Expo West Music and Tech Festival at the ESports ... foster innovation in the natural foods, beverages, and dietary supplement industries, the Nuriv Music ...
(Date:2/2/2019)... ... February 01, 2019 , ... Stay on top of current hot ... food industries. Access to all webinars is free, so be sure to register today ... Visit http://www.xtalks.com to check out our upcoming webinars, or click below to ...
(Date:1/30/2019)... ... January 29, 2019 , ... ... today announced the dosing of the first patient in a phase 1/2 clinical ... serious disease associated with high morbidity and often leads to premature death. ...
Breaking Biology Technology:
(Date:2/22/2019)... ... February 21, 2019 , ... ... have executed a research agreement establishing a collaborative program to work toward applications ... to develop new radiopharmaceutical lead candidates and will explore Fuzionaire Dx’s platform as ...
(Date:2/14/2019)... ... February 14, 2019 , ... This year’s ... will host 80 scientific sessions and 2,100 presentations. Given SOT’s mission to bring ... its OpenLiver™ 3D cell culture model initiative that it recently launched ...
(Date:2/12/2019)... Canada (PRWEB) , ... February 12, 2019 , ... ... it will begin operating under its new name, KEYLEAF. The company will ... of its own plant-based extracts and ingredients as finished products under the new ...
Breaking Biology News(10 mins):